Federal Policy
HRSA Proposes Second Attempt at 340B Rebate Model After Initial Failure
The Health Resources and Services Administration announced a new proposal to allow rebate models in the 340B drug pricing program, marking its second attempt in 2026 after an earlier effort failed. The proposal would change how covered entities receive 340B discounts, moving from upfront discounts to post-purchase rebates. Hospital associations immediately opposed the plan, arguing it would create cash flow problems and administrative burdens for safety-net providers. If finalized, the rebate model could affect how Medicaid providers, particularly disproportionate share hospitals and federally qualified health centers, manage pharmaceutical costs.
Why it mattersMany Medicaid providers rely on 340B savings to fund uncompensated care and patient services, and a shift to rebates could strain their operating cash flow and increase administrative costs.